Mary E Law

Mary E Law, Ph.D.

Research Assistant Professor

Department: MD-PHARMACOLOGY / THERAPEUTICS
Business Phone: (352) 273-9434
Business Email: marylaw@ufl.edu

Teaching Profile

Courses Taught
2019-2025
GMS6531 Medical Pharmacology and Therapeutics III: Endocrine, Musculoskeletal and Reproductive Systems
2019-2021
GMS6530 Medical Pharmacology and Therapeutics II: Cardiovascular, Renal and Respiratory Systems
2020-2023
PAS5026 Pharmacotherapeu 2
2018-2021,2023-2025
GMS6560 Molecules to Man: Past, Present and Future Therapeutic Strategies for Disease
2015-2016,2018-2021,2020-2025
GMS6009 Principles of Drug Action and Therapeutics
2009-2025
DEN6262 Prin of Pharmacology
2014,2016-2022,2022
MDU4002 Introduction to Medical Science Seminar 2
2013
BMS6031 Foundations of Med
2021
GMS6552 Cell Signaling & Therapeutics
2023
BMS6635 Derm and Msk
2023
BMS6634 GI and Hepatology
2024-2025
BMS6632 Endo and Reproduction
2024-2025
BMS6633 The Cv System

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-6625-0534

Publications

2024
DR5 disulfide bonding as a sensor and effector of protein folding stress.
bioRxiv : the preprint server for biology. [DOI] 10.1101/2024.03.04.583390. [PMID] 38496520.
2022
Anticancer Agents Derived from Cyclic Thiosulfonates: Structure‐Reactivity and Structure‐Activity Relationships
ChemMedChem. 17(14) [DOI] 10.1002/cmdc.202200165. [PMID] 35491396.
2022
Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death.
Cancer letters. 534 [DOI] 10.1016/j.canlet.2022.215604. [PMID] 35247515.
2022
Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A.
iScience. 25(7) [DOI] 10.1016/j.isci.2022.104518. [PMID] 35754740.
2021
Repurposing Tranexamic Acid as an Anticancer Agent.
Frontiers in pharmacology. 12 [DOI] 10.3389/fphar.2021.792600. [PMID] 35095503.
2019
A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers.
Oncogene. 38(22):4264-4282 [DOI] 10.1038/s41388-019-0717-6. [PMID] 30718919.
2019
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway.
Cell death discovery. 5 [DOI] 10.1038/s41420-019-0228-9. [PMID] 31839995.
2018
Loss of sirtuin 1 and mitofusin 2 contributes to enhanced ischemia/reperfusion injury in aged livers.
Aging cell. 17(4) [DOI] 10.1111/acel.12761. [PMID] 29774638.
2018
The unfolded protein response as a target for anticancer therapeutics.
Critical reviews in oncology/hematology. 127:66-79 [DOI] 10.1016/j.critrevonc.2018.05.003. [PMID] 29891114.
2017
Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Oncotarget. 8(17):28971-28989 [DOI] 10.18632/oncotarget.15952. [PMID] 28423644.
2016
CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment.
Breast cancer research : BCR. 18(1) [DOI] 10.1186/s13058-016-0741-1. [PMID] 27495374.
2016
Sirtuin 1 suppresses mitochondrial dysfunction of ischemic mouse livers in a mitofusin 2-dependent manner.
Cell death and differentiation. 23(2):279-90 [DOI] 10.1038/cdd.2015.96. [PMID] 26184910.
2015
Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.
Molecular pharmacology. 88(5):846-52 [DOI] 10.1124/mol.115.099325. [PMID] 26018905.
2015
Novel agents that downregulate EGFR, HER2, and HER3 in parallel.
Oncotarget. 6(12):10445-59 [PMID] 25865227.
2014
Concentration-Dependent Diffusion of Ion-Implanted Silicon in In0.53Ga0.47as
Applied Physics Letters. 105(4) [DOI] 10.1063/1.4892079.
2014
Signaling mechanisms that suppress the cytostatic actions of rapamycin.
PloS one. 9(6) [DOI] 10.1371/journal.pone.0099927. [PMID] 24927123.
2013
Assembly, activation, and substrate specificity of cyclin D1/Cdk2 complexes.
Biochemistry. 52(20):3489-501 [DOI] 10.1021/bi400047u. [PMID] 23627734.
2013
Constitutive Cdk2 activity promotes aneuploidy while altering the spindle assembly and tetraploidy checkpoints.
Journal of cell science. 126(Pt 5):1207-17 [DOI] 10.1242/jcs.117382. [PMID] 23321641.
2013
Field-Induced Defect Morphology in Ni-Gate Algan/Gan High Electron Mobility Transistors
Applied Physics Letters. 103(2) [DOI] 10.1063/1.4813535.
2013
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.
Oncogene. 32(10):1316-29 [DOI] 10.1038/onc.2012.138. [PMID] 22543582.
2013
Reliability Studies of Algan/Gan High Electron Mobility Transistors
Semiconductor Science and Technology. 28(7) [DOI] 10.1088/0268-1242/28/7/074019.
2012
An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch.
Cancer letters. 326(2):183-90 [DOI] 10.1016/j.canlet.2012.08.013. [PMID] 22906417.
2012
TGF-beta antiproliferative effects in tumor suppression.
Frontiers in bioscience (Scholar edition). 4(2):749-66 [PMID] 22202088.
2010
Identification of a small molecule inhibitor of serine 276 phosphorylation of the p65 subunit of NF-kappaB using in silico molecular docking.
Cancer letters. 291(2):217-24 [DOI] 10.1016/j.canlet.2009.10.015. [PMID] 19910110.
2009
A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism.
The Journal of biological chemistry. 284(43):29945-55 [DOI] 10.1074/jbc.M109.055251. [PMID] 19710018.
2009
Identification of genes, including the gene encoding p27Kip1, regulated by serine 276 phosphorylation of the p65 subunit of NF-kappaB.
Cancer letters. 275(1):139-49 [DOI] 10.1016/j.canlet.2008.10.007. [PMID] 19038492.
2008
Effects of Hydrogen On the Radiation Response of Bipolar Transistors: Experiment and Modeling
IEEE Transactions on Nuclear Science. 55(6):3039-3045 [DOI] 10.1109/TNS.2008.2009353.
2008
Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.
Neoplasia (New York, N.Y.). 10(11):1240-52 [PMID] 18953433.
2008
Tumors Initiated By Constitutive Cdk2 Activation Contain An Invasive Basal Component
Virchows Archiv. 452:S147-S148
2007
Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression.
Cancer research. 67(7):3135-44 [PMID] 17409420.
2006
Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes.
Cancer research. 66(2):1070-80 [PMID] 16424043.
2001
Tandem translocation of chromosomes 22 and 15 with two preserved satellite stalk regions and deletion 22q13.3-qter.
American journal of medical genetics. 104(4):291-4 [PMID] 11754062.

Grants

Jul 2023 ACTIVE
HER1-3 and Death Receptor protein folding as therapeutic vulnerabilities
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Jun 2023 ACTIVE
Reducing racial disparity in breast cancer survival with a novel synthetic-lethal strategy
Role: Co-Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Jul 2022 ACTIVE
Novel Breast Cancer Therapeutics Targeting a Unique Subset of Disulfide Isomerases
Role: Co-Investigator
Funding: FL BREAST CANCER FOU
Jul 2020 – Jun 2023
Regulation of Death Receptor 5 folding and apoptotic signaling by AGR2
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Jul 2019 – Dec 2020
Dual mechanisms of DDA antitumor activity: Induction of tumor cell apoptosis and vascular disruption
Role: Co-Investigator
Funding: FL BREAST CANCER FOU
Jul 2018 – Dec 2020
A new approach for eradicating metastatic, drug-resistant breast cancers
Role: Co-Investigator
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH
Feb 2018 – May 2019
Synthetic lethal strategy for killing EGFR+/HER2+ cancers
Role: Co-Investigator
Funding: FL BREAST CANCER FOU

Contact Details

Phones:
Business:
(352) 273-9434
Emails:
Business:
marylaw@ufl.edu
Addresses:
Business Mailing:
PO Box 100267
GAINESVILLE FL 32610
Business Street:
1200 NEWELL DRIVE ARB R5-152
GAINESVILLE FL 32610